EMBL Keynote Lecture - Targeting CD8+ T cells: A Paradigm Shift in Treating Cerebral Malaria?

EMBL Keynote Lecture - Targeting CD8+ T cells: A Paradigm Shift in Treating Cerebral Malaria?

Title history
  • EMBL Keynote Lecture - Targeting CD8+ T cells: A Paradigm Shift in Treating Cerebral Malaria? — observed on 20261026-1637 UTC (YouTube)

by Brittany Riggle · View the channel on PSI

Life & Natural Systems Medicine & Health MJCDiseases and disordersMJCMImmunology
🎙 Brittany Riggle 👥 16K 📅 July 28, 2020 ⏱ 30 min 👁 1K 📄 original study 🧭 2026-10-26
Available in: English (current) Français

Keywords

cerebral malariaCD8 T cellsglutamine antagonistDONimmunotherapy

Summary

Brittany Riggle presents her research on the role of CD8+ T cells in cerebral malaria (CM) and proposes a glutamine antagonist (DON) as a potential adjunctive therapy. She begins by describing the global burden of malaria, with CM causing about half a million deaths annually, mainly in African children under five. The Blantyre Malaria Project autopsy study identified three pathological patterns of CM, with the third group showing low sequestration of infected red blood cells, suggesting alternative causes. In the mouse model (experimental cerebral malaria, ECM), CD8+ T cells are essential for pathogenesis, and mechanistic studies show that parasite-specific CD8+ T cells arrest on brain vasculature and release cytotoxic molecules leading to blood-brain barrier breakdown. Using rational drug design, DON, a glutamine analog, was found to rescue mice even in late stages of ECM, reversing MRI changes associated with fatal outcomes. To translate this to humans, Riggle’s team performed multiplex immunohistochemistry on post-mortem brain samples from children with and without CM, finding significant CD3+CD8+ T cell engagement with the cerebrovasculature in CM cases, particularly in the venous vasculature. HIV co-infection altered the distribution to an abluminal pattern. The presence of Granzyme B suggests targeted killing. These findings provide human corroboration for the CD8+ T cell hypothesis and a rationale for testing DON in clinical trials. The talk concludes with a proposed phase I/II study in Malawi, aiming to evaluate safety and efficacy.

232 words

Critical Evaluation

Value of the Information & Strength of the Argument

The value of this presentation lies in its direct human evidence linking CD8+ T cells to cerebral malaria, filling a gap between mouse models and human disease. The argumentation is solid: the speaker systematically presents mouse data, then human tissue findings, and connects them to a therapeutic hypothesis. She acknowledges uncertainties (e.g., the exact mechanism of DON) and uses logical reasoning to propose a clinical trial. The use of quantitative histology and blinded analysis adds rigor. The discussion of prior clinical trials of DON provides a safety and dosing framework, strengthening the feasibility of the proposed studies.

Scientific Rigor, Source Quality, Title Accuracy

The presentation demonstrates strong scientific rigor: methods are described in detail (multiplex immunohistochemistry, vessel selection, blinding), and the sample size (34 brain samples) is modest but combined with clear statistics. Sources cited are the Blantyre Malaria Project and a suggestion from Jonathan Powell, but no explicit publications are referenced, limiting traceability. The title is accurate and evocative, matching the content’s central claim of a paradigm shift. While no comments were provided for analysis, the talk’s structure and responsiveness to questions reflect a well-received conference presentation.

197 words

Title / Content Match

The title poses a question about a paradigm shift, and the talk provides evidence supporting CD8+ T cells' role and a potential therapy, directly addressing the title.

Quality & Reliability

8/10

The talk presents original research from a reputable institution (NIH) at an EMBL conference, with clear methodology, data, and discussion of limitations. The findings are significant but not yet peer-reviewed in this format.

Key Moments

Markers derived by PSI from the transcript: the creator did not define chapters.

Cited Sources

  • Blantyre Malaria Project — Cited as the source of a seminal autopsy study on cerebral malaria pathology, providing 103 autopsies and identifying three pathological patterns.

Contribution & Novelties

This presentation provides novel human evidence that CD8+ T cells are present and engaged in cerebral malaria, using multiplex immunohistochemistry on post-mortem tissue. It also proposes a repurposed drug (DON) as a therapy, with promising mouse data and a clear translation pathway. The identification of a potential mechanism (glutamine metabolism and glutamate excitotoxicity) adds to the understanding of cerebral malaria pathogenesis.

Pour aller plus loin :

  • Cerebral malaria — Overview of cerebral malaria, its definition, epidemiology, and pathology.
  • CD8+ T cell — Description of CD8+ T cells, their function, and role in immune responses.
  • 6-Diazo-5-oxo-L-norleucine (DON) — Chemical compound used as a glutamine antagonist, with historical clinical use in oncology.

110 words

Radar Profile

The radar profile indicates a very high technical level (9) and high reliability (8), with solid information quantity and quality (both 8). This reflects an expert-level presentation with rigorous methodology, though the narrow focus and single-study nature may limit breadth.

Reliability 8/10